Fig. 6From: Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigensA checkpoint inhibitor trial enrolled 74 patients diagnosed with advanced lung cancer. Venous blood draws were collected followed by initiation of their ICI treatment regimen. Adverse events were continuously observed; tumor responses were regularly monitored. Best radiologic response was used as the observed response for analysis in our study. The serum samples collected pretreatment were analyzed on the FSP/Antibody assays to develop models of predicted response and adverse event. NP non-progressor, P progressor, R responder, NR non-responder, Acc accuracy, Class classifiedBack to article page